Revisiting phage therapy: new applications for old resources.

The success of phage therapy is dependent on the development of strategies able to overcome the limitations of bacteriophages as therapeutic agents, the creation of an adequate regulatory framework, the implementation of safety protocols, and acceptance by the general public. Many approaches have been proposed to circumvent phages' intrinsic limitations but none have proved to be completely satisfactory. In this review we present the major hurdles of phage therapy and the solutions proposed to circumvent them. A thorough discussion of the advantages and drawbacks of these solutions is provided and special attention is given to the genetic modification of phages as an achievable strategy to shape bacteriophages to exhibit desirable biological properties.

[1]  S. Abedon,et al.  Phage therapy pharmacology phage cocktails. , 2012, Advances in applied microbiology.

[2]  V. Fischetti,et al.  Bacteriophage lysins as effective antibacterials. , 2008, Current opinion in microbiology.

[3]  M. Momol,et al.  Phage therapy for plant disease control. , 2010, Current pharmaceutical biotechnology.

[4]  K. Murphy.  The λ gam protein inhibits RecBCD binding to dsDNA ends , 2007 .

[5]  A. Henein.  What are the limitations on the wider therapeutic use of phage? , 2013, Bacteriophage.

[6]  Jeffrey E. Barrick,et al.  Bacteriophages use an expanded genetic code on evolutionary paths to higher fitness , 2014, Nature chemical biology.

[7]  C. Rm.  Phage therapy: past history and future prospects. , 1999 .

[8]  S. Abedon,et al.  Phage therapy in clinical practice: treatment of human infections. , 2010, Current pharmaceutical biotechnology.

[9]  F. D'Herelle.  On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux. 1917. , 2007, Research in microbiology.

[10]  K. Miyanaga,et al.  Alteration of tail fiber protein gp38 enables T2 phage to infect Escherichia coli O157:H7. , 2005, Journal of biotechnology.

[11]  N. Cook,et al.  The crystal structure of lambda-Gam protein suggests a model for RecBCD inhibition. , 2007, Journal of molecular biology.

[12]  S. Abedon,et al.  Bacteriophage host range and bacterial resistance. , 2010, Advances in applied microbiology.

[13]  J. Dolan,et al.  Use of Genetically Engineered Phage To Deliver Antimicrobial Agents to Bacteria: an Alternative Therapy for Treatment of Bacterial Infections , 2003, Antimicrobial Agents and Chemotherapy.

[14]  Łusiak-SzelachowskaMarzanna,et al.  Phage neutralization by sera of patients receiving phage therapy. , 2014 .

[15]  U. Qimron,et al.  Efficient engineering of a bacteriophage genome using the type I-E CRISPR-Cas system , 2014, RNA biology.

[16]  Chad W. Euler,et al.  Synergism between a Novel Chimeric Lysin and Oxacillin Protects against Infection by Methicillin-Resistant Staphylococcus aureus , 2010, Antimicrobial Agents and Chemotherapy.

[17]  M. Clokie,et al.  Clostridium difficile phages: still difficult? , 2014, Front. Microbiol..

[18]  S. Abedon,et al.  Phage cocktails and the future of phage therapy. , 2013, Future microbiology.

[19]  Xiaomei Zhou,et al.  Identification and analysis of recombineering functions from Gram-negative and Gram-positive bacteria and their phages , 2008, Proceedings of the National Academy of Sciences.

[20]  Eric C. Keen.  Phage Therapy: Concept to Cure , 2012, Front. Microbio..

[21]  B. Wanner,et al.  One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Frank Buchholz,et al.  A new logic for DNA engineering using recombination in Escherichia coli , 1998, Nature Genetics.

[23]  C. Merril,et al.  An amino acid substitution in a capsid protein enhances phage survival in mouse circulatory system more than a 1000-fold. , 2005, Virus research.

[24]  L. Goodridge.  Designing phage therapeutics. , 2010, Current pharmaceutical biotechnology.

[25]  R. Carlton,et al.  Phage therapy: past history and future prospects. , 1999, Archivum immunologiae et therapiae experimentalis.

[26]  W. Hardt,et al.  PEGylation of bacteriophages increases blood circulation time and reduces T‐helper type 1 immune response , 2008, Microbial biotechnology.

[27]  H. Brüssow.  What is needed for phage therapy to become a reality in Western medicine? , 2012, Virology.

[28]  Timothy K Lu,et al.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy , 2009, Proceedings of the National Academy of Sciences.

[29]  Mahmoud Y. Alkawareek,et al.  Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro. , 2012, FEMS immunology and medical microbiology.

[30]  K. Miyanaga,et al.  Toward rational control of Escherichia coli O157:H7 by a phage cocktail , 2004, Applied Microbiology and Biotechnology.

[31]  C. Sassetti,et al.  Mycobacterial recombineering. , 2015, Methods in molecular biology.

[32]  M. Cotten,et al.  Transferrin-polycation-DNA complexes: the effect of polycations on the structure of the complex and DNA delivery to cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Behr,et al.  High-efficiency transfection of primary human keratinocytes with positively charged lipopolyamine:DNA complexes. , 1994, The Journal of investigative dermatology.

[34]  S. Cartinhour,et al.  Recombineering Using RecTE from Pseudomonas syringae , 2010, Applied and Environmental Microbiology.

[35]  S. Reardon.  Phage therapy gets revitalized , 2014, Nature.

[36]  W. Han,et al.  A Method for Generation Phage Cocktail with Great Therapeutic Potential , 2012, PloS one.

[37]  Remo Guidieri.  Res , 1995, RES: Anthropology and Aesthetics.

[38]  D. Hilbert,et al.  Lysis-deficient bacteriophage therapy decreases endotoxin and inflammatory mediator release and improves survival in a murine peritonitis model. , 2005, Surgery.

[39]  Tamás Fehér,et al.  Bacteriophage recombineering in the lytic state using the lambda red recombinases , 2012, Microbial biotechnology.

[40]  U. Bläsi,et al.  Therapy of Experimental Pseudomonas Infections with a Nonreplicating Genetically Modified Phage , 2004, Antimicrobial Agents and Chemotherapy.

[41]  W. Fortuna,et al.  Phage neutralization by sera of patients receiving phage therapy. , 2014, Viral immunology.

[42]  D. Helinski,et al.  Contained use of Bacteriophages: Risk Assessment and Biosafety Recommendations , 2010 .

[43]  J. Klumpp,et al.  Endolysins as antimicrobials. , 2012, Advances in virus research.

[44]  Jan Borysowski,et al.  Bacteriophage Endolysins as a Novel Class of Antibacterial Agents , 2006, Experimental biology and medicine.

[45]  V. Fischetti,et al.  Bacteriophage lytic enzymes: novel anti-infectives. , 2005, Trends in microbiology.

[46]  J. Gill,et al.  Phage choice, isolation, and preparation for phage therapy. , 2010, Current pharmaceutical biotechnology.

[47]  H. Krisch,et al.  Phage-Antibiotic Synergy (PAS): β-Lactam and Quinolone Antibiotics Stimulate Virulent Phage Growth , 2007, PloS one.

[48]  M. Gottesman,et al.  Characterization of bacteriophage lambda reverse as an Escherichia coli phage carrying a unique set of host-derived recombination functions. , 1974, Journal of molecular biology.

[49]  S. Moineau,et al.  CRISPR-Cas: an efficient tool for genome engineering of virulent bacteriophages , 2014, Nucleic acids research.

[50]  M. Loessner,et al.  Bacteriophage endolysins as novel antimicrobials. , 2012, Future microbiology.

[51]  C. Merril,et al.  Long-circulating bacteriophage as antibacterial agents. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[52]  E. Vandamme.  Phage therapy and phage control: to be revisited urgently!! , 2014 .

[53]  S. Abedon,et al.  Pros and cons of phage therapy , 2011, Bacteriophage.

[54]  M. Piuri,et al.  Recombineering , 2012, Bacteriophage.

[55]  Sylvain Moineau,et al.  Bacteriophage resistance mechanisms , 2010, Nature Reviews Microbiology.

[56]  M. Piuri,et al.  BRED: A Simple and Powerful Tool for Constructing Mutant and Recombinant Bacteriophage Genomes , 2008, PloS one.

[57]  I. Huys,et al.  Taking Bacteriophage Therapy Seriously: A Moral Argument , 2014, BioMed research international.

[58]  H. Ackermann.  Frequency of morphological phage descriptions in the year 2000 , 2001, Archives of Virology.

[59]  J. Norris,et al.  Prokaryotic gene therapy to combat multidrug resistant bacterial infection , 2000, Gene Therapy.

[60]  James J. Collins,et al.  Dispersing biofilms with engineered enzymatic bacteriophage , 2007, Proceedings of the National Academy of Sciences.

[61]  C. Merril,et al.  Escherichia coli K1's Capsule Is a Barrier to Bacteriophage T7 , 2005, Applied and Environmental Microbiology.

[62]  Rob Lavigne,et al.  Learning from Bacteriophages - Advantages and Limitations of Phage and Phage-Encoded Protein Applications , 2012, Current protein & peptide science.

[63]  Juan A Hermoso,et al.  Taking aim on bacterial pathogens: from phage therapy to enzybiotics. , 2007, Current opinion in microbiology.

[64]  Anni-Maria Örmälä,et al.  Phage therapy , 2013, Bacteriophage.